India ranks 5th among US pharma suppliers, contributing roughly 6% of the total US pharmaceutical imports. Despite being behind countries like Ireland, Switzerland, and Germany, India plays a crucial role in the US pharma market, particularly in generics and biosimilars. The country’s strong presence highlights its growing importance in global pharmaceutical supply chains.

With US policies such as tariffs on imported drugs, India’s position as a major exporter could face significant challenges, potentially affecting revenues and necessitating strategic adjustments by Indian pharma companies.

The post India Ranks 5th Among US Pharma Exporters appeared first on India Podcast.

India supplies approximately 45% of generic drugs and 15% of biosimilars used in the US. In FY-24, India exported $8.7 billion worth of pharmaceutical products to the US, out of a total $27.9 billion in global pharma exports. For many Indian pharma companies, the US accounts for 30-50% of their revenue, making them highly vulnerable to this new policy.

The tariff could lead to increased costs, reduced competitiveness, and disrupted supply chains, forcing Indian companies to reconsider strategies, including setting up manufacturing units in the US or exploring alternative markets. Industry analysts view this as a major turning point in India-US pharma trade relations.

The post Trump’s 100% Pharma Tariff: A Severe Blow to India appeared first on India Podcast.